Charles River Laboratories Presents Robust Program At Neuroscience 2016

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of leading Central Nervous System (CNS) and neurological disease experts is presenting 25 scientific posters and one podium presentation, both independently and collaboratively with clients, at Neuroscience 2016, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together over 30,000 researchers from more than 80 countries, is taking place from November 12-16 in San Diego, California.

"The field of neuroscience is rapidly changing and evolving," said Patrick Sweeney, Managing Director of Charles River Discovery Services. "At this year's conference, we will host two scientific discussions on the development of therapeutics for aging and the in vitro and in vivo aspects of drug discovery. We see Neuroscience 2016 as an important opportunity for our experts to collaborate with top scientists from across the globe, sharing our scientific expertise and learning from colleagues."

Among the posters the Charles River team will present are innovative tools and applications for research targeting Huntington's, Alzheimer's, Parkinson's, Multiple Sclerosis, Duchenne Muscular Dystrophy, and other neurological disorders. Noteworthy examples include:
  • A collaboration with the University of Eastern Finland and Kuopio University Hospital on the use of dynamic PET imaging. (Dynamic PET Imaging with Arterial Input Function of Lipopolysaccharide-Induced Neuroinflammation in Rat)
  • A collaboration with Cure Huntington's Disease Initiative (CHDI) on the utilization of Rho kinase inhibitors for Huntington's disease therapeutics. (Progress Towards Potent, Selective and Brain Penetrant Rho Kinase Inhibitors Suitable for a Proof-of-Concept Study in HD Models)
  • The study of altered nerve cell function in Huntington's disease models. (Investigation of Corticostriatal Synaptic Transmission and Cerebellar Purkinje Neuron Firing in the R6/2 Mouse Model of Huntington's Disease by Using Multi-Electrode Arrays)

Additionally, the Charles River team, in conjunction with Sage Therapeutics, will participate in a nanosymposium titled "Epilepsy: Mechanisms" to discuss an optimized high-throughput screening approach to identify positive allosteric modulators of N-methyl-D-aspartate glutamate receptors (NMDARs), which are promising therapeutic targets for numerous neurological indications. This symposium will be held on Monday, November 14, 2016. Nikolai Fedorov, Principal Scientist, Discovery Screening Services at Charles River, will present at 10:00am PST. As a part of its continued focus on high-throughput screening as a mechanism for studying CNS, Charles River recently expanded its ion channel capabilities through the addition of a Sophion Qube 384-well automated patch-clamp platform.

A full schedule of Charles River's activities during Neuroscience 2016 is available on our website, and reprints of each poster are available in Charles River's booth (#1619) during the conference. Additionally, CNS experts are available for meetings with those interested in discussing neuroscience research and drug discovery. Throughout the conference, Charles River will be providing live updates on the  Eureka Blog, including reviews of scientific sessions and input on the research being presented.

About the Society for Neuroscience

The  Society for Neuroscience is the world's largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 40,000 members in more than 90 countries and 130 chapters worldwide.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit

View source version on

Copyright Business Wire 2010